RT Journal Article
T1 Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
A1 Fortner, Renée T
A1 Schock, Helena
A1 Le Cornet, Charlotte
A1 Hüsing, Anika
A1 Vitonis, Allison F
A1 Johnson, Theron S
A1 Fichorova, Raina N
A1 Fashemi, Titilayo
A1 Yamamoto, Hidemi S
A1 Tjønneland, Anne
A1 Hansen, Louise
A1 Overvad, Kim
A1 Boutron-Ruault, Marie-Christine
A1 Kvaskoff, Marina
A1 Severi, Gianluca
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Papatesta, Eleni-Maria
A1 La Vecchia, Carlo
A1 Palli, Domenico
A1 Sieri, Sabina
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Mattiello, Amalia
A1 Onland-Moret, N Charlotte
A1 Peeters, Petra H
A1 Bueno-de-Mesquita, H B As
A1 Weiderpass, Elisabete
A1 Quirós, J Ramón
A1 Duell, Eric J
A1 Sanchez-Perez, Maria-Jose
A1 Navarro, Carmen
A1 Ardanaz, Eva
A1 Larrañaga, Nerea
A1 Nodin, Björn
A1 Jirström, Karin
A1 Idahl, Annika
A1 Lundin, Eva
A1 Khaw, Kay-Tee
A1 Travis, Ruth C
A1 Gunter, Marc
A1 Johansson, Mattias
A1 Dossus, Laure
A1 Merritt, Melissa A
A1 Riboli, Elio
A1 Terry, Kathryn L
A1 Cramer, Daniel W
A1 Kaaks, Rudolf
K1 CA125
K1 MUC16
K1 anti-CA125 antibodies
K1 autoantibodies
K1 early detection markers
K1 ovarian cancer
AB CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed
YR 2017
FD 2017-12-11
LK http://hdl.handle.net/10668/11826
UL http://hdl.handle.net/10668/11826
LA en
DS RISalud
RD Apr 17, 2025